Rare cancer of corpus uteri

Rare cancer of corpus uteri (Orphanet code 213569) is a grouping term that encompasses uncommon malignant neoplasms arising from the body of the uterus (the corpus uteri), excluding the more frequently encountered endometrioid adenocarcinoma. This category includes several histologically distinct tumor types such as uterine carcinosarcoma (malignant mixed Müllerian tumor), uterine leiomyosarcoma, endometrial stromal sarcoma, uterine clear cell carcinoma, uterine serous (papillary) carcinoma, and undifferentiated uterine sarcoma, among others. These cancers primarily affect the female reproductive system but may spread to the pelvic organs, peritoneum, lungs, and other distant sites. Key symptoms commonly include abnormal uterine bleeding (particularly postmenopausal bleeding), pelvic pain or pressure, an enlarging pelvic mass, and unexplained weight loss. Some patients may present with vaginal discharge or symptoms related to metastatic disease. Diagnosis typically involves endometrial biopsy or curettage, imaging studies (ultrasound, CT, or MRI), and surgical staging. Treatment depends on the specific histological subtype, stage, and grade of the tumor. Surgery, usually total hysterectomy with bilateral salpingo-oophorectomy, remains the cornerstone of management. Adjuvant therapies may include radiation therapy, chemotherapy (often platinum-based or anthracycline-based regimens), hormonal therapy, or targeted therapies depending on the tumor type. Prognosis varies widely among subtypes; high-grade serous carcinomas and carcinosarcomas tend to have a poorer prognosis compared to low-grade endometrial stromal sarcomas. Ongoing research into molecular profiling and immunotherapy is expanding treatment options for these rare uterine malignancies.

Common questions about Rare cancer of corpus uteri